K9N5Q8 (SPIKE_MERS1) Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
Spike glycoprotein UniProtKBInterProInteractive Modelling
1353 aa; Sequence (Fasta) ;
1 identical sequence: Human betacoronavirus 2c England-Qatar/2012: M1RNL5
Available Structures
53 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| MERS-CoV spike complex with S41 neutralizing antibody Fab Class3 (2u1d RBD with 2Fab) |
Heteromer | |||||
| Assess | ||||||
| MERS-CoV spike complex with S41 neutralizing antibody Fab Class2 (1u2d RBD with 2Fab) |
Heteromer | |||||
| Assess | ||||||
| MERS-CoV spike complex with S41 neutralizing antibody Fab Class1 (1u2d RBD with 1Fab) |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | 21×NAG; 21×NAG; | ||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | |||||
| Assess | ||||||
| MERS S0 trimer in complex with variable domain of antibody G2 |
Heteromer | 18×NAG; 3×NAG; 3×NAG; 18×NAG; | ||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | 21×NAG; 21×NAG; | ||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | |||||
| Assess | ||||||
| MERS-CoV spike complex with S41 neutralizing antibody Fab Class4 (2u1d RBD with 3Fab) |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4 |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with neutralizing antibody 0722(state 2) |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with neutralizing antibody 111 state1 |
Heteromer | |||||
| Assess | ||||||
| MERS S ectodomain trimer in complex with neutralizing antibody 0722 (state 1) |
Heteromer | |||||
| Assess | ||||||
| MERS-CoV spike N-terminal domain and 7D10 scFv complex |
Heteromer | 1×NAG; 1×NAG; 2×NAG; 1×NAG; 3×NAG; | ||||
| Assess | ||||||
| Crystal Structure of MERS-CoV S1-NTD bound with G2 Fab |
Heteromer | 3×NAG; 2×NAG; 1×NAG; 2×NAG; 6×SO4; 1×DHF; | ||||
| Assess | ||||||
| Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD |
Heteromer | 2×NAG; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of the MERS-CoV RBD bound by the neutralizing single-domain antibody MERS VHH-55 |
Heteromer | |||||
| Assess | ||||||
| Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV… |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vacci… |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Complex structure of bat CD26 and MERS-RBD |
Heteromer L5LQ33; | 13×NAG; 4×NAG; 11×NAG; | ||||
| Assess | ||||||
| Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vacci… |
Heteromer | 2×NAG; | ||||
| Assess | ||||||
| Crystal structure of Middle-East Respiratory Syndrome (MERS) coronavirus neutralizing antibody JC57… |
Heteromer | 1×SO4; | ||||
| Assess | ||||||
| Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV… |
Heteromer | |||||
| Assess | ||||||
| S41 neutralizing antibody Fab(MERS-CoV) |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of Receptor binding domain of MERS-CoV and KNIH90-F1 Fab complex |
Heteromer | 17×EDO; 2×NAG; | ||||
| Assess | ||||||
| Structure of MERS-CoV RBD in complex with a fully human antibody MCA1 |
Heteromer | 1×NAG; 1×EDO; | ||||
| Assess | ||||||
| Crystal structure of potent neutralizing antibody CDC2-C2 in complex with MERS-CoV S1 RBD |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Crystal Structure of the Human Coronavirus MERS HR1 motif in complex with pan-CoVs inhibitor EK1 |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of MERS-CoV spike stem helix peptide in complex with Fab of broadly neutralizing … |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of MERS-CoV spike stem helix peptide in complex with Fab of broadly neutralizing … |
Heteromer | |||||
| Assess | ||||||
| MERS-CoV S stem helix peptide bound to Fab22 |
Heteromer | |||||
| Assess | ||||||
| Fab 1249A8-MERS Stem Helix Complex |
Heteromer | 9×MG; 1×CL; | ||||
| Assess | ||||||
| B6 Fab fragment bound to the MERS-CoV spike stem helix peptide |
Heteromer | 3×GOL; | ||||
| Assess | ||||||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-5 |
Heteromer P01902; P61769; | |||||
| Assess | ||||||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-2 |
Heteromer P01902; P61769; | |||||
| Assess | ||||||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-3 |
Heteromer P01902; P61769; | |||||
| Assess | ||||||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide I5A |
Heteromer P01902; P61769; | |||||
| Assess | ||||||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-1 |
Heteromer P01902; P61769; | |||||
| Assess | ||||||
| Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with MERS-CoV-derive… |
Heteromer A0A125R585; P61769; | |||||
| Assess | ||||||
| MERS-CoV spike complex | homo-3-mer | |||||
| Assess | ||||||
| MERS-CoV S bound to the broadly neutralizing B6 Fab fragment (C3 refinement) | homo-3-mer | 6×NAG; 12×NAG; 3×NAG; 3×NAG; 6×NAG; 3×FOL; 21×NAG; 3×SIA; | ||||
| Assess | ||||||
| Prefusion structure of MERS-CoV spike glycoprotein, three-fold symmetry | homo-3-mer | 30×NAG; | ||||
| Assess | ||||||
| Prefusion structure of MERS-CoV spike glycoprotein, conformation 2 | homo-3-mer | |||||
| Assess | ||||||
| Prefusion structure of MERS-CoV spike glycoprotein, conformation 1 | homo-3-mer | |||||
| Assess | ||||||
| Structure of the MERS-CoV fusion core | homo-3-mer | |||||
| Assess | ||||||
| Crystal structure of dimeric MERS-CoV receptor binding domain | homo-2-mer | 1×NAG; | ||||
| Assess | ||||||
| Crystal Structure of MERS-CoV S1 N-terminal Domain | monomer | 8×NAG; 1×FOL; 1×MPD; 1×IMD; | ||||
| Assess | ||||||
| Structure of the N-terminal domain (NTD) of MERS-CoV spike protein | monomer | 2×NAG; | ||||
| Assess | ||||||
| Structure of unbound MERS-CoV spike receptor-binding domain (England1 strain). | monomer | 2×NAG; | ||||
| Assess | ||||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5w9k.1.L | monomer | 0.74 | 99.69 | |||
| Assess | ||||||
| 5w9n.1.J | monomer | 0.73 | 99.69 | |||
| Assess | ||||||
| 8sak.1.A | monomer | 0.69 | 69.77 | |||
| Assess | ||||||